Suppr超能文献

神经免疫学争议:多发性硬化症、疫苗接种、SARS-CoV-2 及其他困境。

Controversies in neuroimmunology: multiple sclerosis, vaccination, SARS-CoV-2 and other dilemas.

机构信息

Departamento de Neurología, Fundación Santa Fe de Bogotá, Bogotá, D.C., Colombia.

Programa de Residente en Neurología Clínica, Universidad El Bosque, Bogotá, D.C., Colombia.

出版信息

Biomedica. 2022 Oct 31;42(Sp. 2):78-99. doi: 10.7705/biomedica.6366.

Abstract

Neuroimmunology is a discipline that increasingly broadens its horizons in the understanding of neurological diseases. At the same time, and in front of the pathophysiological links of neurological diseases and immunology, specific diagnostic and therapeutic approaches have been proposed. Despite the important advances in this discipline, there are multiple dilemmas that concern and filter into clinical practice. This article presents 15 controversies and a discussion about them, which are built with the most up-to-date evidence available. The topics included in this review are: steroid decline in relapses of multiple sclerosis; therapeutic recommendations in MS in light of the SARS-CoV-2 pandemic; evidence of vaccination in multiple sclerosis and other demyelinating diseases; overview current situation of isolated clinical and radiological syndrome; therapeutic failure in multiple sclerosis, as well as criteria for suspension of disease-modifying therapies; evidence of the management of mild relapses in multiple sclerosis; recommendations for prophylaxis against Strongyloides stercolaris; usefulness of a second course of immunoglobulin in the Guillain-Barré syndrome; criteria to differentiate an acute-onset inflammatory demyelinating chronic polyneuropathy versus Guillain-Barré syndrome; and, the utility of angiotensin-converting enzyme in neurosarcoidosis. In each of the controversies, the general problem is presented, and specific recommendations are offered that can be adopted in daily clinical practice.

摘要

神经免疫学是一门学科,它在理解神经系统疾病方面的视野越来越广。与此同时,在神经系统疾病和免疫学的病理生理学联系面前,已经提出了特定的诊断和治疗方法。尽管该学科取得了重要进展,但仍有许多难题困扰着并影响着临床实践。本文提出了 15 个争议点,并对这些争议点进行了讨论,这些争议点是基于最新的现有证据构建的。本综述涵盖的主题包括:多发性硬化症复发时类固醇的减少;SARS-CoV-2 大流行背景下多发性硬化症的治疗建议;多发性硬化症和其他脱髓鞘疾病疫苗接种的证据;孤立的临床和放射学综合征的现状概述;多发性硬化症的治疗失败,以及停止疾病修正治疗的标准;轻度多发性硬化症复发的管理证据;预防 Strongyloides stercolaris 的建议;在吉兰-巴雷综合征中使用第二疗程免疫球蛋白的效用;区分急性发作炎症性脱髓鞘慢性多发性神经病与吉兰-巴雷综合征的标准;以及血管紧张素转换酶在神经结节病中的应用。在每一个争议点中,都提出了一般性问题,并提出了可以在日常临床实践中采用的具体建议。

相似文献

1
Controversies in neuroimmunology: multiple sclerosis, vaccination, SARS-CoV-2 and other dilemas.
Biomedica. 2022 Oct 31;42(Sp. 2):78-99. doi: 10.7705/biomedica.6366.
3
Guillain-​Barré Syndrome Associated with COVID-19 Vaccination.
Emerg Infect Dis. 2021 Dec;27(12):3175-3178. doi: 10.3201/eid2712.211634. Epub 2021 Oct 14.
4
A 50-Year-Old Patient with Guillain-Barré Syndrome after COVID-19: A Case Report.
Medicina (Kaunas). 2021 Jul 29;57(8):775. doi: 10.3390/medicina57080775.
7
Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series.
Eur J Neurol. 2022 Feb;29(2):555-563. doi: 10.1111/ene.15147. Epub 2021 Oct 31.
8
SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome.
Clinics (Sao Paulo). 2022 Jun 13;77:100064. doi: 10.1016/j.clinsp.2022.100064. eCollection 2022.
9
Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain-Barré syndrome.
Acta Neurol Belg. 2020 Oct;120(5):1067-1075. doi: 10.1007/s13760-020-01421-3. Epub 2020 Jul 21.
10
Review article on COVID-19 and Guillain-Barré syndrome.
Front Biosci (Schol Ed). 2021 Jun 30;13(1):97-104. doi: 10.52586/S555.

本文引用的文献

1
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
J Neuroimmunol. 2021 Aug 15;357:577627. doi: 10.1016/j.jneuroim.2021.577627. Epub 2021 Jun 7.
2
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835. doi: 10.1177/17562864211012835. eCollection 2021.
3
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.
4
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Brain. 2020 Sep 1;143(9):2742-2756. doi: 10.1093/brain/awaa231.
5
Effects of MS disease-modifying therapies on responses to vaccinations: A review.
Mult Scler Relat Disord. 2020 Oct;45:102439. doi: 10.1016/j.msard.2020.102439. Epub 2020 Aug 1.
6
Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.
Front Immunol. 2020 Jul 14;11:1443. doi: 10.3389/fimmu.2020.01443. eCollection 2020.
7
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29.
8
COVID-19 in people with multiple sclerosis: A global data sharing initiative.
Mult Scler. 2020 Sep;26(10):1157-1162. doi: 10.1177/1352458520941485. Epub 2020 Jul 14.
9
Protecting people with multiple sclerosis through vaccination.
Pract Neurol. 2020 Dec;20(6):435-445. doi: 10.1136/practneurol-2020-002527. Epub 2020 Jul 6.
10
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
JAMA Neurol. 2020 Sep 1;77(9):1079-1088. doi: 10.1001/jamaneurol.2020.2581.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验